AfatinibAntineoplastic AgentsCarcinoma, Non-Small-Cell Lung
Dr. Mark Huberman, MD
NPI1477583441
- Medicare services, 2017
- 306
- Part D claims, 2017
- 148
- Publications
- 29
- Clinical trials
- 1
- Industry payments
- $88,381
- Practice address
- 44 Grafton St, Newton, MA 02459-1545
- Practice phone
- Call (617) 610-4097
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Huberman's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Mark Huberman is a medical oncologist in Newton, Massachusetts
Dr. Huberman practices in Newton, Massachusetts.
Dr. Huberman's NPI, 1477583441, was assigned on July 4, 2006. Dr. Huberman holds Massachusetts license 37935.
NPI and contact details
- NPI
- 1477583441NPI Registry (opens in a new tab)
- NPI enumeration date
- July 4, 2006
- NPI status
- Active
- Practice phone
- (617) 610-4097
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. Mark Huberman's practice address is in Newton, Massachusetts
Dr. Huberman's practice address in the NPI Registry is 44 Grafton St, Newton, MA 02459-1545. The practice phone is (617) 610-4097.
- NPI Registry address44 Grafton St, Newton, MA 02459-1545Phone(617) 610-4097
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. Mark Huberman's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Huberman practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Huberman's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Huberman practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Mark Huberman is one of 290 medical oncologists in Massachusetts
Medical oncology is Dr. Huberman's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Huberman is licensed in Massachusetts.
Specialties and state licenses
- Medical oncology, MassachusettsPrimary
Medical oncologists near Dr. Huberman
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Mark Huberman billed Medicare for 306 services in 2017
CMS data shows 306 Medicare services from Dr. Huberman across 2 procedure codes in 2017, all of them office visits. Medicare paid $15,539 for them. Every service was in a facility, such as a hospital, rather than an office.
Medicare services, 2017306
Paid by Medicare$15,539
Procedure codes2
Dr. Huberman's Medicare services by type, 2016 to 2017
- 2016
- 2017
- Office and hospital visits
- 2016: 6692017: 30654%
Dr. Huberman compared with the Massachusetts median for medical oncologists, 2017
- Dr. Huberman
- Massachusetts median
- Medicare services
- 306vs 26018% above
- Part D claims
- 148vs 632.3 times
Medians across 259 medical oncologists in Massachusetts with Dmand AI profiles that report each measure.
Dr. Huberman's most billed Medicare procedure codes, 2017
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Huberman?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Huberman and other medical oncologists in Massachusetts.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Mark Huberman wrote 148 Medicare Part D claims in 2017
In 2017, Dr. Huberman wrote 148 Medicare Part D claims. They cover 10 drugs, with $9,798 in total drug cost. In 2016, CMS named 228 claims across 11 drugs.
Part D claims, 2017148
Drugs named by CMS10
Total drug cost$9,798
Dr. Huberman's most prescribed drugs by claims, 2017
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2016 to 2017
- 2016
- 2017
- Claims for drugs CMS names
- 2016: 2282017: 14835%
Drugs named by CMS: 10 in 2017, 11 in 2016.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find medical oncologists like Dr. Huberman by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Mark Huberman has 29 publications on record
Dmand AI links 29 papers to Dr. Huberman, published from 2011 to 2021. 2016 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Huberman has published most often in J Thorac Oncol. Dr. Huberman's most frequent co-authors are Daniel Botelho Costa, MD, Deepa Rangachari, MD and Erik Eduardo Folch, MD, MS.
Papers29
Years published2011 to 2021
Dr. Huberman's papers by year, 2011 to 2021
Topics Dr. Huberman writes about most
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Adenocarcinoma
- Anaplastic Lymphoma Kinase
- Exons
Dr. Huberman's most frequent co-authors
- Daniel Botelho Costa, MD27 shared papers
- Deepa Rangachari, MD17 shared papers
- Erik Eduardo Folch, MD, MS8 shared papers
Recent publications by Dr. Huberman
Adenocarcinoma of LungAntineoplastic AgentsCell Line, Tumor
Lung Cancer
B7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell Lung
See who Dr. Huberman researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Huberman works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Mark Huberman has worked on 1 clinical trial
Dmand AI links Dr. Huberman to 1 clinical trial. Open Payments lists research payments to Dr. Huberman that name 1 trial.
Investigators on the most trials with Dr. Huberman
- John Ross Clark1 shared trial
- Conrad Wittram, MBCHB1 shared trial
Recent clinical trials with Dr. Huberman
$29,700 in research paymentsIpilimumab
Sources: Open Payments (CMS), 2025 data, released July 7, 2026; Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Mark Huberman received $88,381 in industry payments from 2016 to 2018
CMS Open Payments shows 26 general payments to Dr. Huberman from 3 drug and device companies from 2016 to 2018. Consulting fees make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $88,340. It also lists 9 research payments totaling $36,000 from 2016 to 2019, naming 1 clinical trial.
General payments to Dr. Huberman by program year, 2016 to 2018
General payments to Dr. Huberman by kind, 2016 to 2018
$88.4Kin total
- Consulting fees$88,340100%
- Food and beverage$410%
Companies that paid Dr. Huberman the most, 2016 to 2018
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Mark Huberman's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Mark Huberman
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Mark Huberman's NPI number?
Dr. Mark Huberman's NPI number is 1477583441. It was assigned on July 4, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Mark Huberman?
Dr. Mark Huberman is a medical oncologist in Newton, Massachusetts. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Mark Huberman practice?
Dr. Huberman practices at 44 Grafton St, Newton, MA 02459-1545.
What is Dr. Mark Huberman's office phone number?
The practice phone on file for Dr. Huberman is (617) 610-4097.
What is Dr. Mark Huberman's medical license number?
Dr. Huberman holds Massachusetts license 37935.
Does Dr. Mark Huberman accept Medicare?
Yes. CMS data shows Dr. Huberman billed Medicare for 306 services in 2017.
What services does Dr. Mark Huberman bill to Medicare?
In 2017, Dr. Huberman's most billed Medicare services were office visit, established patient (99214) and office visit, established patient (99213).
What drugs does Dr. Mark Huberman prescribe most?
In 2017 Medicare Part D data, Dr. Huberman's most prescribed drugs by claims were Anastrozole, Dexamethasone and Warfarin Sodium.
Has Dr. Mark Huberman received payments from drug or device companies?
CMS Open Payments shows $88,381 in general payments to Dr. Huberman from 3 companies from 2016 to 2018. The largest total came from Merck Sharp & Dohme Corporation.
How long has Dr. Mark Huberman been practicing?
Dr. Huberman's NPI was assigned in 2006.
Does Dr. Mark Huberman do research?
Dmand AI links 29 publications to Dr. Huberman, published from 2011 to 2021. Dr. Huberman has worked on 1 clinical trial.
Who does Dr. Mark Huberman publish with?
Dr. Huberman's most frequent co-authors are Daniel Botelho Costa, MD (27 shared papers), Deepa Rangachari, MD (17 shared papers) and Erik Eduardo Folch, MD, MS (8 shared papers).
Selling to medical oncology practices?
See medical oncologists in Massachusetts by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card